Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.420 +0.190 (+5.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,871,952
Open 3.280
Bid (Size) 3.440 (3,500)
Ask (Size) 3.450 (1,700)
Prev. Close 3.230
Today's Range 3.250 - 3.430
52wk Range 2.560 - 6.440
Shares Outstanding 95,598,665
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Altimmune Q2 Earnings Call Highlights ↗
Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial ↗
Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying... 
Via MarketBeat

Performance

YTD
-2.6%
-2.6%
1 Month
+12.9%
+12.9%
3 Month
+26.2%
+26.2%
6 Month
-3.4%
-3.4%
1 Year
-3.9%
-3.9%

More News

Read More
News headline image
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗
Via MarketBeat
News headline image
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗
Via MarketBeat
Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Altimmune (ALT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Altimmune Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
Via Stocktwits
News headline image
Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Government Lawsuit
News headline image
ALT Stock Rallies 4% — What Does Retail Think? ↗
Via Stocktwits
News headline image
Why Are Investors Looking At Altimmune Stock? ↗
Via Benzinga
News headline image
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗
Via Stocktwits
News headline image
Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗
Via Stocktwits
News headline image
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗
Via Stocktwits
News headline image
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?
Yes, Altimmune, Inc. - Common Stock is publicly traded.
What exchange does Altimmune, Inc. - Common Stock trade on?
Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Altimmune, Inc. - Common Stock?
The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market
What is the current price of Altimmune, Inc. - Common Stock?
The current price of Altimmune, Inc. - Common Stock is 3.420
When was Altimmune, Inc. - Common Stock last traded?
The last trade of Altimmune, Inc. - Common Stock was at 09/04/26 04:00 PM ET
What is the market capitalization of Altimmune, Inc. - Common Stock?
The market capitalization of Altimmune, Inc. - Common Stock is 326.95M
How many shares of Altimmune, Inc. - Common Stock are outstanding?
Altimmune, Inc. - Common Stock has 327M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.